인슐린 전달 디바이스 시장 예측(-2030년) : 제품, 유통 채널, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Insulin Delivery Devices Market is accounted for $14.9 billion in 2023 and is expected to reach $28.0 billion by 2030 growing at a CAGR of 9.4% during the forecast period. Insulin delivery devices are tools or systems designed to administer insulin to individuals with diabetes. They're used to regulate blood sugar levels by delivering insulin into the body. These devices come in various forms, such as insulin syringes, insulin pens, insulin pumps, and insulin jet injectors. They provide different methods for insulin administration, allowing individuals to manage their condition more effectively based on their lifestyle, preferences, and insulin needs.

According to International Diabetes Federation (IDF), the adult diabetes population in 2021 was approximately 537 million, and this number is expected to increase by 643 million in 2030.

Market Dynamics:

Driver:

Rising prevalence of diabetes

The rising prevalence of diabetes has fuelled advancements in insulin delivery devices. Innovations cater to diverse needs, offering convenience and precision. From traditional syringes to advanced insulin pumps and pens, technology has revolutionized management. Smart devices integrate monitoring with delivery, enhancing patient autonomy. These devices not only improve adherence but also enhance quality of life for individuals managing diabetes, marking a significant stride in diabetes care.

Restraint:

Technical issues

Insulin delivery devices can encounter technical glitches impacting insulin administration. Malfunctions pose risks of incorrect insulin delivery, leading to hyper or hypoglycemia. Mechanical failures, like needle jams or pump blockages, necessitate immediate replacement, potentially causing inconvenience or interruptions in insulin therapy. These technical drawbacks highlight the importance of user vigilance and regular device checks to ensure seamless and safe insulin delivery. These are the factors restraining the growth of the market.

Opportunity:

Adoption of facilitative initiatives

Facilitative initiatives in insulin delivery devices have revolutionized diabetic care. Advances like smart pumps, continuous glucose monitoring integration, and user-friendly interfaces streamline management. Additionally, tech-driven features, such as automated insulin delivery algorithms, offer precise, real-time adjustments. Embracing these innovations not only empowers patients but also fosters a collaborative approach between healthcare providers and individuals managing diabetes. These are the factors propelling the growth of the market.

Threat:

High cost

The high cost of insulin delivery devices poses significant disadvantages, primarily affecting accessibility and affordability for individuals managing diabetes. This financial burden often restricts access to essential equipment, leading to inadequate or inconsistent treatment. Limited affordability can result in compromised health outcomes due to the inability to consistently monitor blood sugar levels or administer insulin effectively. These are the aspects limiting the growth of the market.

Covid-19 Impact:

Manufacturing slowdowns, transportation issues, and increased demand for medical supplies led to intermittent shortages and delays in availability for certain devices. The pandemic emphasized the importance of device sanitization and safety measures. Manufacturers and users paid more attention to ensuring that insulin delivery devices were properly cleaned and maintained to minimize the risk of infection.

The insulin pens segment is expected to be the largest during the forecast period

The insulin pens segment is expected to be the largest during the forecast period. ts advantages over other products. Its high adoption rate, user-friendly design, and growing consumer appeal were some of the factors that led to this segment's highest revenue share. A significant contributing aspect to the high share is the increasing emphasis that manufacturers are placing on innovation and advances. Therefore, it is anticipated that in the near future, product innovations will drive the demand for insulin pens.

The home care segment is expected to have the highest CAGR during the forecast period

The home care segment is expected to have the highest CAGR during the forecast period due to increasing awareness of diabetes care. Insulin devices used at home reduce waiting times, hospital or clinic fees, and visitation expenses. The cutting-edge gadgets, which come in the form of pens, injectors, and pumps, are compact, extremely portable, and always useful. Because of their increased usability and increased accessibility, insulin users are choosing self-care diabetes control solutions.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. The market in the region has been significant, driven by various factors such as the increasing prevalence of diabetes, technological advancements in insulin delivery systems, and the growing aging population. Additionally, collaborations between healthcare providers, manufacturers, and research institutions for developing innovative insulin delivery devices have further propelled market growth in the region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The market in the region has been witnessing significant growth due to various factors such as the rising prevalence of diabetes, increasing awareness about advanced insulin delivery technologies, and improving healthcare infrastructure in several countries. Moreover, government initiatives promoting diabetes management and technological advancements in insulin delivery systems contribute to the market's expansion.

Key players in the market

Some of the key players in Insulin Delivery Devices market include Abbott Laboratories, Novo Nordisk A/S, Wockhardt Ltd., Medtronic, F. Hoffmann-La Roche, Ltd., Becton, Dickinson and Company, Sanofi, Eli Lilly and Company, Biocon Ltd., Roche, Insulet Corporation, B Braun Melsungen AG, Tandem Diabetes Care, Embecta Corporation and Ypsomed AG.

Key Developments:

In June 2023, Novo Nordisk entered negotiations of acquiring BIOCORP, which specialized in the design and development of medical devices. This was done for the development of FlexTouch Pen with Mallya, an add-on Bluetooth device.

In Feb 2023, Lilly and IABL, the largest healthcare provider collaborated to provide high-quality and affordable insulin in Bangladesh.

Types Covered:

• Insulin Pumps
• Insulin Pens
• Insulin Pen Needles
• Insulin Syringes
• Insulin Inhalers
• Insulin Jet Injectors
• Other Types

Distribution Channels Covered:

• Online Sales
• Hospital Pharmacies
• Retail Pharmacies

End Users Covered:

• Homecare
• Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Insulin Delivery Devices Market, By Product

• 5.1 Introduction
• 5.2 Insulin Pumps
  • 5.2.1 Tubeless
  • 5.2.2 Tethered
• 5.3 Insulin Pens
  • 5.3.1 Reusable
  • 5.3.2 Disposable
• 5.4 Insulin Pen Needles
  • 5.4.1 Safety
  • 5.4.2 Standard
• 5.5 Insulin Syringes
• 5.6 Insulin Inhalers
• 5.7 Insulin Jet Injectors
• 5.8 Other Types

6 Global Insulin Delivery Devices Market, By Distribution Channel

• 6.1 Introduction
• 6.2 Online Sales
• 6.3 Hospital Pharmacies
• 6.4 Retail Pharmacies

7 Global Insulin Delivery Devices Market, By End User

• 7.1 Introduction
• 7.2 Homecare
• 7.3 Clinics
• 7.4 Other End Users

8 Global Insulin Delivery Devices Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Abbott Laboratories
• 10.2 Novo Nordisk A/S
• 10.3 Wockhardt Ltd.
• 10.4 Medtronic
• 10.5 F. Hoffmann-La Roche, Ltd.
• 10.6 Becton, Dickinson and Company
• 10.7 Sanofi
• 10.8 Eli Lilly and Company
• 10.9 Biocon Ltd.
• 10.10 Roche
• 10.11 Insulet Corporation
• 10.12 B Braun Melsungen AG
• 10.13 Tandem Diabetes Care
• 10.14 Embecta Corporation
• 10.15 Ypsomed AG